Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
HC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR)
HC Wainwright restated Vir Biotechnology's stock 'buy' rating with a $110.00 price objective. Other analysts also maintain 'buy' ratings, resulting in an average 'Moderate Buy' rating and $36.40 price target. Vir Biotechnology's stock opened at $9.64, with a market cap of $1.32 billion. Insiders and institutional investors have been active in trading the stock.
Barclays Has Lowered Expectations for Vir Biotechnology Stock Price
Barclays lowered Vir Biotechnology's price objective from $28.00 to $26.00 with an 'overweight' rating. Other firms like Needham & Company LLC and HC Wainwright maintain 'buy' ratings with respective targets of $19.00 and $110.00. Vir Biotechnology's stock opened at $9.64 with a market cap of $1.32 billion. The company reported a revenue of $2.38 million for the quarter, missing estimates. Insiders sold shares, and institutional investors like Blue Trust Inc. and Quest Partners LLC increased their stakes.
Analysts Conflicted on These Healthcare Names: Vir Biotechnology (VIR) and Moderna (MRNA)
Analysts from Leerink Partners maintain Buy ratings on Vir Biotechnology (VIR) with a $18.00 target and Sell on Moderna (MRNA) with no target specified. The consensus for VIR is a Moderate Buy with a $32.67 target, while Moderna has a Moderate Buy consensus with a $97.62 target.
Vir Biotechnology EVP Vanina de Verneuil Sells Shares
Vanina de Verneuil, EVP and General Counsel at Vir Biotechnology, sold 3,750 shares for $32,332 on Nov 1 and Nov 5, 2024, under a Rule 10b5-1 plan to cover tax obligations. She now directly owns 61,370 shares.
Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
Myriam Hernandez Alvarez, with degrees from Ecuador, USA, and Spain, collaborates with Edgar Torres H on Seeking Alpha. No stock positions held, and no compensation received beyond Seeking Alpha. Seeking Alpha's past performance disclaimer emphasizes no guarantees and no official recommendations.
Vir Biotechnology, Inc. SEC 10-Q Report
Vir Biotechnology's Q3 2024 Form 10-Q reports $2.4M in revenues, $(231.3)M in operating loss, and $(213.7)M in net loss. The company highlights progress in CHD and CHB programs, solid tumors, and preclinical pipeline. Strategic restructuring includes workforce reduction and a Sanofi license agreement. Financial risks and operational challenges persist.
Vir Biotechnology (NASDAQ:VIR) Given New $26.00 Price Target at Barclays
Barclays reduces Vir Biotechnology's target price from $28.00 to $26.00, maintaining an 'overweight' rating. Other analysts also issue 'buy' ratings, resulting in a 'Moderate Buy' consensus with an average target price of $36.40. Insider trading and hedge fund activity are noted, with 65.32% of the stock owned by institutional investors.
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. After Its ...
Vir Biotechnology's Q3 results missed expectations, with revenues of $2.4m falling 57% short and a per-share loss of $1.56, 63% below forecasts. Analysts predict a 61% revenue decline in 2025 and a narrower loss of $3.58 per share. The consensus price target remains at $29.88, with wide-ranging estimates from $10.00 to $110.00, indicating difficulty in valuing the company accurately. Vir Biotechnology is expected to underperform the broader industry, which forecasts 21% annual revenue growth.
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are ...
Vir Biotechnology's Q4 results missed expectations, with revenues of $2.4m and a per-share loss of $1.56. Analysts predict a 61% revenue decline in 2025 to $30.4m, with a loss per share reducing to $3.58. The consensus price target remains $29.88, indicating no major change in intrinsic value. Despite this, Vir Biotechnology is expected to underperform compared to the broader industry.
Vir Biotechnology price target lowered to $26 from $28 at Barclays
Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of bots. Account typically reactivates within 24 hours; contact support if still disabled.
© Copyright 2024. All Rights Reserved by MedPath